Orbis Medicines
A Medicinal Chemist at Orbis Medicines will combine deep expertise in synthetic organic chemistry with a strong interest in enabling technologies like automation and parallel synthesis. Reporting to the VP of Medicinal Chemistry, the role involves driving innovative chemistry solutions to accelerate the discovery and optimization of next-generation oral macrocycle therapeutics. The position requires contributing to hit-to-lead and lead optimization activities while supporting the development of scalable synthetic routes and early CMC considerations.
Orbis Medicines is a biopharmaceutical company focused on oral macrocycle drug discovery, developing next-generation small molecule drugs called nCycles that can target diseases traditionally treated with injectable biologic therapies. The company's proprietary nGen platform uses high-throughput chemistry, DNA-encoded libraries, and AI-driven deep learning to systematically explore macrocycle chemical space and identify orally bioavailable drug candidates. Orbis Medicines aims to provide oral alternatives to blockbuster biologic drugs, enabling treatment of a broader patient population across multiple therapeutic areas.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Orbis Medicines.
Orbis Medicines didn’t post a salary, so this is our estimate from similar listings.
6% above the average for this role